Theranostic Risk Stratification for Thyroid Cancer in the Genomic Paradigm

Abstract

Theranostics define diagnostic evaluations directing patient-specific therapeutic decisions. Molecular theranostics involves genomic, transcriptomic, proteomic, metabolomic and finally phenonic definitions thyroid cancer differentiation. It is the functional differentiation that determines the sensitivity and accuracy of RAI imaging as well as the effectiveness of RAI treatment. Total thyroidectomy is performed to empower an anticipated RAI treatment. A preoperative determination of the genomic and transcriptomic profile of the tumor is a strong predictor of response to therapeutic interventions. This article discusses the oncopathophysiologic basis of the theranostic risk stratification approach.

Keywords

• theranostics
• radioactive iodine theranostics
• differentiated thyroid cancer
• mis-differentiated thyroid cancer
• radioactive iodine refractory
• radioactive iodine indifferent